Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2014-03-11 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by XTL Biopharmaceuticals Ltd. on March 10, 2014. Form 6-K is a report of a foreign private issuer submitted to the SEC, typically used to provide current reports or updates that are not annual or quarterly reports. The content includes a postponement notice of an Extraordinary General Meeting due to lack of quorum, with details about the rescheduled meeting. There are no financial statements or detailed financial analysis present, and the document is not an annual or quarterly report. It is also not a proxy solicitation or voting results announcement, but rather a regulatory update about the meeting postponement. Given the nature of Form 6-K filings and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-03-11 Hebrew (modern)
Immediate Report
AGM Information Classification · 95% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations). The key content explicitly states: 'Attached hereto is a report on *Adjoument of Special Meeting of Shareholders due to lack of quorum.*' This indicates the document itself is an announcement about an event (adjournment of a meeting) and points to an attached PDF. Since the core subject is related to a shareholder meeting (Special Meeting) and its outcome (adjournment), it relates to corporate governance or meeting procedures. While it is an announcement, the specific nature points towards the mechanics of a shareholder meeting rather than a general regulatory filing (RNS) or a proxy solicitation (PSI). However, the most fitting category for announcements related to shareholder meetings, especially those concerning procedural outcomes like adjournment due to lack of quorum, is often grouped with AGM materials or general regulatory announcements. Given the options, and since it is an immediate report concerning a shareholder meeting's status, it is closely related to AGM procedures. If the document were the actual voting results, DVA would apply. Since it is an announcement about the meeting's status (adjournment), and it is not a standard 10-K, ER, or IR, it falls best under the general regulatory/meeting announcement category. Given the specific mention of a 'Special Meeting of Shareholders', and the lack of a specific 'Meeting Adjournment' code, I will classify this as a general Regulatory Filing (RNS) as it is an immediate report that doesn't fit the specific definitions of ER, 10-K, or AGM-R (which usually implies presentation materials). However, upon re-evaluation, the subject matter is highly specific to shareholder meetings. Since AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this concerns a Special Meeting adjournment, it is a procedural announcement related to shareholder meetings. Given the limited options, RNS is the safest fallback for an immediate report announcement, but if we consider the context of shareholder meetings, it is a procedural update. I will lean towards RNS as it is an 'Immediate Report' announcement, not the final materials of the meeting itself.
2014-03-11 English
FORM 6K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports the postponement of an Extraordinary General Meeting due to lack of quorum and provides details about the rescheduled meeting. The document is short (4206 characters) and primarily serves as a regulatory announcement rather than a full report. It does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or management discussion. It is also not a proxy solicitation or voting results announcement. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a meeting postponement and does not fit other specific categories.
2014-03-10 English
Other Report or Announcement
Regulatory Filings
2014-03-06 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is a regulatory filing announcement from XTL BIOPHARMACEUTICALS LTD, reported via MAGNA on 06/03/2014. The key indicator is the table entry stating: "Attached hereto is a report on *Preliminary prospectus supplement re offering*" with the file name *Prelim_pro_isa.pdf*. This structure—announcing the publication of a specific financial/offering document—fits the definition of a Report Publication Announcement (RPA). It is not the prospectus itself, but the notice that it has been published. The content relates to a prospectus supplement, which is a financing/capital activity, but the document's function here is the announcement of publication.
2014-03-06 English
FORM F-3
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 registration statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for the offering and sale of securities (American Depositary Receipts). The text includes detailed information about the securities being registered, the offering process, risk factors, business overview, financial review, management, and legal matters. This type of filing is related to capital raising activities and financing. It is not an earnings release, annual report, or other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2014-03-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.